Prospective cohort study by InspECT on safety and efficacy of electrochemotherapy for cutaneous tumors and metastases depending on ulceration

• Published in: Journal der Deutschen Dermatologischen Gesellschaft Vol. 20; no. 4; pp. 470 - 481
• Main Authors: Claussen, Carla Sophie, Moir, Graeme, Bechara, Falk G., Orlando, Antonio, Matteucci, Paolo, Mowatt, David, Clover, Anthony James P., Mascherini, Matteo, Gehl, Julie, Muir, Tobian, Sersa, Gregor, Groselj, Ales, Odili, Joy, Giorgione, Roberto, Campana, Luca Giovanni, Bertino, Giulia, Curatolo, Pietro, Banerjee, Shramana, Kis, Erika, Quaglino, Pietro, Pritchard‐Jones, Rowan, De Terlizzi, Francesca, Grischke, Eva‐Maria, Kunte, Christian
• Format: Journal Article
• Language: English; German
• Published: Germany Wiley Subscription Services, Inc 01.04.2022
• Subjects: Bleomycin - adverse effects; Chemotherapy; Cohort analysis; Electrochemotherapy - adverse effects; Electrochemotherapy - methods; Electroconvulsive therapy; Humans; Lesions; Metastases; Metastasis; Pain; Pain - etiology; Patients; Prospective Studies; Skin Neoplasms - pathology; Treatment Outcome; Tumors
• ISSN: 1610-0379; 1610-0387
• DOI: 10.1111/ddg.14699

Summary Background Electrochemotherapy (ECT) is an effective local treatment for cutaneous tumors. The aim of this study was to compare the effectiveness of ECT in ulcerated vs. non‐ulcerated tumors and investigate the effect on tumor‐associated symptoms. Methods Twenty cancer centers in the International Network for Sharing Practices on Electrochemotherapy (InspECT) prospectively collected data. ECT was performed following ESOPE protocol. Response was evaluated by lesion size development. Pain, symptoms, performance status (ECOG‐Index) and health status (EQ‐5D questionnaire) were evaluated. Results 716 patients with ulcerated (n = 302) and non‐ulcerated (n = 414) cutaneous tumors and metastases were included (minimum follow‐up of 45 days). Non‐ulcerated lesions responded to ECT better than ulcerated lesions (complete response 65 % vs. 51 %, p = 0.0061). Only 38 % (115/302) with ulcerated lesions before ECT presented with ulcerated lesions at final follow‐up. Patients with ulcerated lesions reported higher pain and more severe symptoms compared to non‐ulcerated lesions, which significantly and continuously improved following ECT. In non‐ulcerated lesions however, pain spiked during the treatment. No serious adverse events were reported. Conclusions ECT is a safe and effective local treatment for cutaneous tumors. While ECT improves symptoms especially in patients with ulcerated lesions, data suggest the implementation of a perioperative pain management in non‐ulcerated lesions during ECT.